Milmiga (Liraglutide)

Liraglutide, the active ingredient in Milmiga, is a GLP‑1 receptor agonist presented as a subcutaneous injection for subcutaneous use. It is indicated for the management of type 2 diabetes mellitus and for chronic weight management in adults with obesity, and helps improve glycaemic control.

GNH USA supplies Milmiga as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring product integrity from manufacturing to delivery. Our network covers major regions across Europe, Asia, Africa and the Americas.

Liraglutide acts on the glucagon‑like peptide‑1 pathway to improve metabolic control in several chronic conditions. - Type 2 diabetes mellitus: improves glycaemic control and reduces HbA1c levels. - Obesity: promotes weight loss through appetite suppression and reduced caloric intake. - Cardiovascular risk reduction: lowers incidence of major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.

Liraglutide may cause a range of adverse reactions, varying from mild to serious. Common Side Effects: - Nausea: transient feeling of sickness, often early in therapy. - Vomiting: occasional mild episodes. - Headache: mild to moderate head pain. Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Thyroid C‑cell tumors: potential risk observed in animal studies. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas.

Before using Milmiga, consider the following precautions. - Renal function assessment: evaluate kidney status before initiating therapy. - Pancreatitis monitoring: discontinue if signs of acute pancreatitis appear. - Thyroid disease evaluation: avoid in patients with medullary thyroid carcinoma or MEN2. - Concomitant hypoglycemic agents: adjust dose of insulin or sulfonylureas to reduce hypoglycemia risk. - Pregnancy and lactation: use only if benefits outweigh potential risks; consult healthcare provider. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Liraglutide can interact with several medicines; review the following. Major Interactions (Avoid): - Insulin: combined use may cause severe hypoglycemia. - Sulfonylureas: increased risk of low blood glucose levels. Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, monitor coagulation. - Diuretics: risk of dehydration, monitor electrolytes. - Oral contraceptives: may affect glycemic control, monitor blood glucose.